Merck & Co., Inc. (MRK)
| Market Cap | 274.34B |
| Revenue (ttm) | 64.24B |
| Net Income (ttm) | 19.03B |
| Shares Out | 2.48B |
| EPS (ttm) | 7.56 |
| PE Ratio | 14.63 |
| Forward PE | 14.27 |
| Dividend | $3.40 (3.08%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 10,891,023 |
| Open | 110.87 |
| Previous Close | 110.99 |
| Day's Range | 110.22 - 112.48 |
| 52-Week Range | 73.31 - 112.90 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 115.27 (+4.29%) |
| Earnings Date | Feb 3, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $115.27, which is an increase of 4.29% from the latest price.
News
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Revolution is developing drugs that target a molecular driver of cancers.
Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck
Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list
Merck on Thursday said any changes to the U.S. child and adolescent immunization schedule should rest on comprehensive data and guidance from vaccine experts, after federal health officials shifted se...
Merck in talks to buy biotech Revolution Medicines, FT reports
Merck is in talks to buy cancer drug developer Revolution Medicines , the Financial Times reported on Thursday, citing people familiar with the matter.
Cramer's Stop Trading: Merck
CNBC's Jim Cramer explains why he is keeping an eye on shares of Merck.
Merck: Fundamentals Amplified By A Momentum Breakout
Merck has surged nearly 30% since my prior bullish call, reflecting strong share price momentum. MRK fundamentals are robust, underpinned by stellar financial performance and promising regulatory deve...
The Big 3: XRT, MRK, CAT
@Theotrade's Don Kaufman is bullish on the SPDR E&P Retail ETF (XRT) and Caterpillar (CAT) but tilts bearish on Merck (MRK). He explains his stance on today's Big 3 and offers example options trades f...
Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation
Merck could lose up to $630 million in Gardasil revenue this year now that the U.S. no longer recommends three doses of the HPV shot in the childhood vaccine schedule, according to Jefferies analysts.
Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO
BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive Off...
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluati...
Merck to Complete Acquisition of Cidara Therapeutics
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Complete Acquisition of Cidara Therapeutics.
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3.
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference.
Top 10 High-Yield Dividend Stocks For January 2026
My high-yield dividend watchlist aims for quality stocks at attractive valuations, with a long-term CAGR target of 12%. In December 2025, the watchlist gained 0.03%, outperforming VYM and SPY, though ...
Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites
The Dow Jones Industrial Average hit record all-time highs in 2025 with many of the components ending the year higher. Along with serving as a well-known barometer of overall market health, the index ...
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining tract...
Merck: Framework For Success
Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, b...
Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis
Merck earns a cautious "Buy" rating due to an intriguing valuation and clear, somewhat manageable uncertainties, especially post-Keytruda expiry in 2028. MRK's heavy reliance on Keytruda poses risk, b...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy
The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill and its cancer therapy, making them the latest additions to the fast-track pr...
